Roger Dumoulin-White, President and CEO of Theralase stated, "If our PDC technology is proven effective in cancer patients, through human clinical trials slated to commence in early 2015, the implications of this discovery are game changing for both Theralase and for the cancer patients affected. As demonstrated in the first research paper, the ability to destroy the original cancer and also program the body's immune system to prevent its recurrence, after only a single treatment, is nothing short of miraculous. In the second research paper, demonstration of the ability to destroy virtually all types of cancers, whether normoxic or hypoxic in nature, opens up the potential of new treatment options for a wide range of cancers in various early and advanced stages."